Cefiderocol for Infection with Carbapenem-Resistant Acinetobacter baumannii (CRAB)

Cefiderocol-based treatment regimens were associated with lower 30-day mortality than colistin-based regimens against CRAB.

Cefiderocol is a novel siderophore cephalosporin approved by the FDA for treating complicated urinary tract infections and hospital-acquired or ventilator-associated pneumonia caused by carbapenem-resistant Gram-negative bacteria. A randomized trial of cefiderocol versus best available therapy for patients with such infections (CREDIBLE CR) found unexpectedly higher mortality in the subset of patients with carbapenem-resistant Acinetobacter baumannii (CRAB) who received cefiderocol — and unexpectedly lower mortality in the control arm, contrary to real-world experience (as well as trials comparing the newer beta-lactam antibiotics with colistin).

To clarify these findings, Falcone and colleagues conducted a single-center observational study …

Reviewing Author

George Sakoulas, MD

Disclosures

Consultant/Advisory BoardParatek Pharmaceuticals; Nestle Corp.; AbbVie; Shionogi

Speaker’s BureauAllergan/AbbVie; Paratek Pharmaceuticals; Nestle Corp.

RoyaltiesUpToDate

Editorial BoardsAntimicrobial Agents and Chemotherapy; Open Forum Infectious Diseases